Despite the effectiveness of HDAC inhibitors in pre-clinical models only four HDAC inhibitors, including suberanoyl hydroxamic acid (SAHA) are currently approved by the US Food and Drug Administration for the treatment of T-cell lymphoma and multiple myeloma [14]. The gene discussed is HDAC9; the disease is AL amyloidosis.